Product
Dual-targeting HER2 and PD-L1 CAR-T cells
1 clinical trial
3 indications
Indication
Peritoneal CarcinomaIndication
pleural effusionIndication
malignantClinical trial
Phase I Study of Specific CAR-T Dual-targeting HER2 and PD-L1 in Patients With Pleural or Peritoneal Metastasis of HER2 Positive CancerStatus: Recruiting, Estimated PCD: 2024-12-30